DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer

Information source: Chong Kun Dang Pharmaceutical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Advanced Solid Cancers

Intervention: CKD-810, Taxotere inj. (Drug); CKD-810, Taxotere inj. (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Chong Kun Dang Pharmaceutical

Official(s) and/or principal investigator(s):
JH Kang, Principal Investigator, Affiliation: The Catholic University of Korea


The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.

Clinical Details

Official title: Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pharmacokinetics of CKD-810 and Taxotere inj.

Secondary outcome: Safety of CKD-810 and Taxotere inj.

Detailed description: This is a Phase III study designed to evaluate the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer. This study will also assess the safety of the docetaxel in advanced solid cancer patients.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patient is greater than 18 years of age

- Advanced solid tumor

- locally advanced or metastatic breast cancer which docetaxel alone therapy was


- locally advanced or metastatic non-small cell lung cancer which docetaxel alone

therapy was adequate

- locally advanced or metastatic other malignant tumor which docetaxel alone

therapy was adequate

- Patient has a life expectancy of at least 3 months

- Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Absolute neutrophil count ≥ 1,500/㎣

- Platelet count ≥ 100,000/㎣

- Hemoglobin ≥ 9. 0g/dL

- Total Bilirubin ≤ 1. 5 X ULN

- Alkaline Phosphatase ≤ 2. 5 X ULN

- AST/ALT ≤ 2. 0 X ULN

- Serum creatinine ≤ 1. 5 X ULN or Creatinine clearance ≥ 60mL/min(Cockcroft equation)

- Patients should voluntarily sign a written informed consent before study entry

Exclusion Criteria:

- If present, any active bacterial infection that have to parenteral antibiotic

therapy. Patients may be included if their infection has resolved to totally or controlled state

- Brain metastasis with neurologic symptom

- History of unstable cardiac arrhythmia, congestive heart failure or myocardial

infarction within 6 months

- Known to test positive for HIV or hepatitis B or C

- Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of

study medication. (Patients may be included if the patients who need to intake the medication such as cimetidine was keep the same dose continuously at 1 cycle and 2 cycle)

- Peripheral neuropathy ≥ Grade 2

- known resistant or uncontrolled severe hypersensitivity to docetaxel

- History of hypersensitivity reaction to Polysorbate 80

- The female patients of pregnancy, breast feeding or childbearing potential. And the

patients has not laboratory result or the result was a positive serum pregnancy test, also Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements. (In case of menopausal women, keeping menopause at least 12 months. All sexually active male patients must agree to use adequate methods of birth control throughout the study)

- Administration of any other tumor therapy, including chemotherapy, radiotherapy, and

immunotherapy within 4 weeks before the beginning of study treatment. Patients may be included if the radiotherapy was conducted to relieve symptoms and that symptoms recovered to grade 1

- treated with any investigational drugs within 4 weeks before the beginning of study


- Must be treated concurrent administration of other anti-cancer medicine

- Not able to participate to the study, at the discretion of the investigator

Locations and Contacts

Gachon University Gil Hospital, Inchon, Korea, Republic of

The Catholic university of KOREA, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

The Korea University Anam Hospital, Seoul, Korea, Republic of

Ajou University Hospital, Suwon, Korea, Republic of

Dongsan Medical Center, Keimyung University, Taegu, Korea, Republic of

Yeoungnam University Hospital, Taegu, Korea, Republic of

Ulsan University Hospital, Ulsan, Korea, Republic of

Additional Information

Starting date: August 2009
Last updated: December 15, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017